221 related articles for article (PubMed ID: 17617520)
1. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition.
Martin L; Schilder R
J Clin Oncol; 2007 Jul; 25(20):2894-901. PubMed ID: 17617520
[TBL] [Abstract][Full Text] [Related]
2. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
3. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
4. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
6. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
Thornton AD; Ravn P; Winslet M; Chester K
Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in the treatment of ovarian cancer.
Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic anti-VEGF antibodies.
Lien S; Lowman HB
Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
[TBL] [Abstract][Full Text] [Related]
12. The future of targeted therapies in ovarian cancer.
Banerjee S; Gore M
Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
[TBL] [Abstract][Full Text] [Related]
13. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of anti-angiogenic therapy in ovarian cancer (review).
Conteduca V; Kopf B; Burgio SL; Bianchi E; Amadori D; De Giorgi U
Int J Oncol; 2014 May; 44(5):1417-24. PubMed ID: 24626312
[TBL] [Abstract][Full Text] [Related]
15. The role of new agents in the treatment of colorectal cancer.
Ruiz de Erenchun F
Oncology; 2005; 68(2-3):162; author reply 162. PubMed ID: 16097096
[No Abstract] [Full Text] [Related]
16. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
17. Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma.
Rose PG; Roma A
Anticancer Drugs; 2013 Oct; 24(9):986-8. PubMed ID: 23872910
[TBL] [Abstract][Full Text] [Related]
18. Targeting angiogenesis in lung cancer.
Sandler AB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S16-22. PubMed ID: 16459175
[TBL] [Abstract][Full Text] [Related]
19. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for ovarian cancer: current status and new treatments.
Ozols RF
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]